Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte(TM) versus Valchlor(R) for the treatment of cutaneous T-cell lymphoma in Oncology and Therapy, highlighting favorable efficacy and safety outcomes. After 12 weeks, 60% of HyBryte-treated patients achieved treatment success compared to 20% for Valchlor, with greater average improvement and no treatment-related adverse events reported for HyBryte, while Valchlor patients experienced multiple adverse reactions, supporting HyBryte’s potential as a well-tolerated therapy for early-stage CTCL.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer